Segall Bryant & Hamill LLC Boosts Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Segall Bryant & Hamill LLC raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 53,103 shares of the company's stock after purchasing an additional 6,233 shares during the period. Segall Bryant & Hamill LLC owned 0.05% of Neurocrine Biosciences worth $5,873,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. OneDigital Investment Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 2.1% during the 4th quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company's stock valued at $575,000 after purchasing an additional 87 shares in the last quarter. HighPoint Advisor Group LLC raised its stake in Neurocrine Biosciences by 4.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company's stock worth $334,000 after purchasing an additional 96 shares during the period. Huntington National Bank raised its stake in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after acquiring an additional 97 shares during the period. Utah Retirement Systems grew its holdings in Neurocrine Biosciences by 0.6% during the 4th quarter. Utah Retirement Systems now owns 16,583 shares of the company's stock worth $2,264,000 after acquiring an additional 100 shares in the last quarter. Finally, GeoWealth Management LLC raised its stake in Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after acquiring an additional 102 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the firm's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the sale, the director owned 37,491 shares of the company's stock, valued at $4,131,508.20. This trade represents a 44.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jude Onyia sold 59,819 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the completion of the transaction, the insider directly owned 18,289 shares of the company's stock, valued at approximately $2,385,982.94. This trade represents a 76.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 120,251 shares of company stock valued at $14,978,602. 4.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of research reports. HC Wainwright lowered their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research note on Tuesday, April 22nd. Wall Street Zen downgraded shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Canaccord Genuity Group boosted their price target on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. UBS Group upped their target price on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a report on Wednesday, July 9th. Finally, JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 26th. Three analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Trading Up 0.5%

Shares of NBIX stock opened at $134.11 on Friday. The company has a market capitalization of $13.27 billion, a PE ratio of 45.46, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.98. The firm has a fifty day simple moving average of $125.18 and a 200-day simple moving average of $121.53.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The business had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. During the same quarter last year, the firm earned $1.20 earnings per share. Neurocrine Biosciences's revenue was up 11.1% compared to the same quarter last year. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.